Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01292694 · ClinicalTrials.gov registry record · Phase 1
Contribution of Angiotensin II to Supine Hypertension in Autonomic Failure
A Phase 1 study, sponsored by Vanderbilt University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT01292694 is a Phase 1 study that was terminated before completion, run by Vanderbilt University. The registered enrollment target is 12 participants.
The verdict
NCT01292694, a Phase 1 study, was terminated before completion, sponsored by Vanderbilt University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to test the hypothesis that angiotensin II plays a role in the supine hypertension of primary autonomic failure. To determine the contribution of angiotensin II to renin and blood pressure regulation in autonomic failure, patients with multiple system atrophy \[MSA\] or pure autonomic failure \[PAF\] and supine hypertension will undergo medication testing with the angiotensin II receptor blocker losartan. The investigators will compare the biochemical and hemodynamic effects between MSA and PAF patients. In a subset of patients, the investigators will also give the ACE inhibitor captopril. Our primary endpoint will be changes in plasma renin activity, and subsequent components of the circulating renin-angiotensin system, in response to angiotensin II blockade. Our secondary outcome will be changes in hemodynamic measures during administration of these drugs.
Interventions
- DRUG Placebo
- DRUG Losartan
- DRUG Captopril
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2011-03 |
| Est. Completion | 2017-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01292694
The ClinicalTrials.gov registry entry for NCT01292694 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01292694 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01292694 about?
NCT01292694 is a clinical study titled "Contribution of Angiotensin II to Supine Hypertension in Autonomic Failure". The purpose of this study is to test the hypothesis that angiotensin II plays a role in the supine hypertension of primary autonomic failure. To determine the contribution of angiotensin II to renin and blood pressure regulation in autonomic failure, patients with multiple system atrophy \[MSA\] or ...
What is the current status of trial NCT01292694?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2011-03. Estimated completion is 2017-03.
What interventions are being tested in trial NCT01292694?
The interventions under investigation include: Placebo (DRUG), Losartan (DRUG), Captopril (DRUG).
Who is sponsoring clinical trial NCT01292694?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.